Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating the safety and effects of tilrekimig, a study medicine being tested for severe asthma. The trial focuses on people who have had severe asthma for at least 12 months and experienced two or more asthma attacks in the past year. This phase 3 study aims to understand how tilrekimig compares to placebo shots in improving asthma symptoms and reducing attack rates. Participants will receive either tilrekimig or a placebo through subcutaneous injections administered at the study clinic. The study uses a randomized, double-blind design with parallel groups to compare outcomes. Treatment and observation take place over a 52-week period, with additional monitoring of safety up to 64 weeks. During the study, participants will have regular assessments including lung function tests, symptom questionnaires, and monitoring for asthma exacerbations and safety events. Researchers will measure the annual rate of asthma attacks, lung function changes, quality of life, and other asthma control indicators. The total duration for participant involvement is up to 64 weeks, including follow-up for adverse events.
Actively Recruiting
Researchers are studying the prevention of recurrent Clostridioides difficile infection CDI in adults aged 18 and older. This Phase IIb clinical trial evaluates the safety and effectiveness of a drug called AZD5148 compared to a placebo. The trial is randomized, double-blind, and placebo-controlled, aiming to reduce the chance of CDI coming back. This study is sponsored by AstraZeneca and focuses on preventing infection recurrence in participants who have recently experienced CDI and are undergoing antibacterial treatment. Participants will be randomly assigned to receive a single dose of either AZD5148 or a placebo, given by either intramuscular injection or intravenous push as decided by the investigator. The treatment is administered once during the antibacterial therapy, which must last between 10 and 28 days. The study involves up to two visits for eligibility confirmation and dosing, followed by up to seven planned visits for monitoring. Participants will also complete an electronic diary and receive follow-up contacts weekly at first, then monthly. Participants will be closely monitored through stool sample collections, symptom tracking, and assessment of any adverse events. Researchers will evaluate the first recurrence of CDI within 91 days, duration and severity of diarrhea symptoms, hospitalizations related to CDI, and any adverse reactions to the study drug. Safety assessments continue for up to 361 days after dosing, including analysis of drug levels and immune responses. The total participation time may extend over a year to fully assess outcomes and safety.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the PyloPlus Urea Breath Test System to confirm the effectiveness of treatment for Helicobacter pylori infection. This multi-center, non-randomized, open-label study includes patients who have been treated for H. pylori within the past six months and aims to compare the PyloPlus system results with other diagnostic methods. The study is sponsored by ARJ Medical, Inc. and is conducted in a Phase 3 setting. Participants will undergo testing with the PyloPlus UBT System, which measures carbon-13 content in breath after ingesting a special urea compound. In addition, patients may have stool antigen testing and a comparator breath test or undergo an endoscopy for rapid urease testing and histology as diagnostic comparisons. The PyloPlus test results are kept blinded from treating physicians, who will manage patient care independently. During the study, participants will provide breath samples analyzed by the PyloPlus UBT Analyzer and may submit stool samples or undergo endoscopy with biopsy. The main outcome measured is the overall percent agreement of the PyloPlus test results compared to standard diagnostic tests within seven days. The study includes safety monitoring and does not influence clinical management decisions based on the investigational test results.